Table IV.
Patients with specific clinical adverse events of incidence over 5%, in at least one treatment group.
| Adverse event | Standard regimen group, n (%) | Aprepitant regimen group, n (%) |
|---|---|---|
| Anorexia | 26 (48.1) | 26 (44.1) |
| Fatigue | 8 (14.8) | 6 (10.2) |
| Diarrhea | 3 (5.6) | 2 (3.4) |
| Constipation | 4 (7.4) | 1 (1.7) |
| Oral mucositis | 3 (5.6) | 1 (1.7) |
| Leukopenia (Grade 3–4) | 11 (20.4) | 12 (20.3) |
| Neutropenia (Grade 3–4) | 11 (20.4) | 15 (25.4) |
| Thrombocytopenia | 7 (13.0) | 4 (6.8) |
| Total | 54 (100) | 59 (100) |
No grade 3 or 4 adverse events were observed except for neutropenia and leukopenia. There were no statistically significant differences in risk of adverse events between the treatment groups.